Archivi autore: Mighty Medic
MightyMedic Workshop on Lipidology and Atherosclerosis – Genoa, Italy – 17 May 2017
HEART UK 31st Annual Medical & Scientific Conference
The Global Gathering For Orphan Drugs
The MIGHTY MEDIC Org FALL SCHOOL of CLINICAL LIPIDOLOGY
X Congresso Aferesi Terapeutica del Gruppo di Studio della Società Italiana di Nefrologia Napoli, 4 – 5 Novembre 2016 Centro Congressi Via Partenope
X Congresso Aferesi Terapeutica del Gruppo di Studio della Società Italiana di Nefrologia Napoli, 4 – 5 Novembre 2016 Centro Congressi Via Partenope
NOVEMBER 11-12, 2016 VIENNA, AUSTRIA
NOVEMBER 11-12, 2016 VIENNA, AUSTRIA
The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia – a post-hoc analysis of a Phase 3, single-arm, open-label trial.
OBJECTIVE: Lomitapide (a microsomal triglyceride transfer protein inhibitor) is an adjunctive treatment for homozygous familial hypercholesterolaemia (HoFH), a rare genetic condition characterised by elevated low-density lipoprotein-cholesterol (LDL-C), and premature, severe, accelerated atherosclerosis. Standard of care for HoFH includes lipid-lowering drugs and lipoprotein apheresis. We conducted a post-hoc analysis using data …
FH Europe 2016
The role of microparticles in inflammation and transfusion: a concise review
Abstract Microparticles are small membrane-bound vesicles, found in body fluids including peripheral blood. Microparticles are an intrinsic part of blood labile products delivered to transfused patients and have active roles in inflammation. They are delimited by a lipid bilayer composed mainly of phospholipids, cholesterol, membrane-associated proteins, intracellular components such as metabolic enzymes, proteins-involved …